357 related articles for article (PubMed ID: 15010854)
1. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
[TBL] [Abstract][Full Text] [Related]
2. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
3. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
[TBL] [Abstract][Full Text] [Related]
4. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Yokogawa T; Okabe H; Kitazato K
Int J Mol Med; 2004 Feb; 13(2):249-55. PubMed ID: 14719131
[TBL] [Abstract][Full Text] [Related]
5. TAS-102: a novel antimetabolite for the 21st century.
Uboha N; Hochster HS
Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
[TBL] [Abstract][Full Text] [Related]
6. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
Sakamoto K; Yokogawa T; Ueno H; Oguchi K; Kazuno H; Ishida K; Tanaka N; Osada A; Yamada Y; Okabe H; Matsuo K
Int J Oncol; 2015; 46(6):2327-34. PubMed ID: 25901475
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
8. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
[TBL] [Abstract][Full Text] [Related]
9. Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer.
Baba T; Kokuryo T; Yamaguchi J; Yokoyama Y; Uehara K; Ebata T; Nagino M
Anticancer Res; 2018 Mar; 38(3):1427-1434. PubMed ID: 29491068
[TBL] [Abstract][Full Text] [Related]
10. TAS-102, a novel antitumor agent: a review of the mechanism of action.
Lenz HJ; Stintzing S; Loupakis F
Cancer Treat Rev; 2015 Nov; 41(9):777-83. PubMed ID: 26428513
[TBL] [Abstract][Full Text] [Related]
11. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
[TBL] [Abstract][Full Text] [Related]
14. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
Tanaka N; Sakamoto K; Okabe H; Fujioka A; Yamamura K; Nakagawa F; Nagase H; Yokogawa T; Oguchi K; Ishida K; Osada A; Kazuno H; Yamada Y; Matsuo K
Oncol Rep; 2014 Dec; 32(6):2319-26. PubMed ID: 25230742
[TBL] [Abstract][Full Text] [Related]
15. A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
Miyamoto Y; Lenz HJ; Baba H
Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869
[TBL] [Abstract][Full Text] [Related]
16. Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity.
Edahiro K; Iimori M; Kobunai T; Morikawa-Ichinose T; Miura D; Kataoka Y; Niimi S; Wakasa T; Saeki H; Oki E; Kitao H; Maehara Y
Mol Cancer Res; 2018 Oct; 16(10):1483-1490. PubMed ID: 29866926
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
El-Naggar M; Ebbing E; Bijnsdorp I; van den Berg J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):413-21. PubMed ID: 24940699
[TBL] [Abstract][Full Text] [Related]
19. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
Temmink OH; de Bruin M; Comijn EM; Fukushima M; Peters GJ
Anticancer Drugs; 2005 Mar; 16(3):285-92. PubMed ID: 15711180
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Nukatsuka M; Nakagawa F; Saito H; Sakata M; Uchida J; Takechi T
Anticancer Res; 2015 Mar; 35(3):1437-45. PubMed ID: 25750295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]